Tatsuya Aonuma1,2, Bruno Moukette1, Satoshi Kawaguchi1, Nipuni P Barupala1, Marisa N Sepúlveda1, Kyle Frick3, Yaoliang Tang4, Maya Guglin3, Subha V Raman3, Chenleng Cai5, Suthat Liangpunsakul6,7, Shinichi Nakagawa8, Il-Man Kim1,3,5. 1. Department of Anatomy, Cell Biology, and Physiology (T.A., B.M., S.K., N.P.B., M.N.S., I.-m.K.), Indiana University School of Medicine, Indianapolis. 2. Now with Division of Cardiology, Nephrology, Pulmonology, and Neurology, Department of Internal Medicine, Asahikawa Medical University, Hokkaido, Japan (T.A.). 3. Krannert Institute of Cardiology (K.F., M.G., S.V.R., I.-m.K.), Indiana University School of Medicine, Indianapolis. 4. Vascular Biology Center, Medical College of Georgia, Augusta University (Y.T.). 5. Wells Center for Pediatric Research (C.C., I.-m.K.), Indiana University School of Medicine, Indianapolis. 6. Division of Gastroenterology and Hepatology (S.L.), Indiana University School of Medicine, Indianapolis. 7. Roudebush Veterans Administration Medical Center, Indianapolis, IN (S.L.). 8. RNA Biology Laboratory, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan (S.N.).
Abstract
BACKGROUND: MicroRNA-150 (miR-150) plays a protective role in heart failure (HF). Long noncoding RNA, myocardial infarction-associated transcript (MIAT) regulates miR-150 function in vitro by direct interaction. Concurrent with miR-150 downregulation, MIAT is upregulated in failing hearts, and gain-of-function single-nucleotide polymorphisms in MIAT are associated with increased risk of myocardial infarction (MI) in humans. Despite the correlative relationship between MIAT and miR-150 in HF, their in vivo functional relationship has never been established, and molecular mechanisms by which these 2 noncoding RNAs regulate cardiac protection remain elusive. METHODS: We use MIAT KO (knockout), Hoxa4 (homeobox a4) KO, MIAT TG (transgenic), and miR-150 TG mice. We also develop DTG (double TG) mice overexpressing MIAT and miR-150. We then use a mouse model of MI followed by cardiac functional, structural, and mechanistic studies by echocardiography, immunohistochemistry, transcriptome profiling, Western blotting, and quantitative real-time reverse transcription-polymerase chain reaction. Moreover, we perform expression analyses in hearts from patients with HF. Lastly, we investigate cardiac fibroblast activation using primary adult human cardiac fibroblasts and in vitro assays to define the conserved MIAT/miR-150/HOXA4 axis. RESULTS: Using novel mouse models, we demonstrate that genetic overexpression of MIAT worsens cardiac remodeling, while genetic deletion of MIAT protects hearts against MI. Importantly, miR-150 overexpression attenuates the detrimental post-MI effects caused by MIAT. Genome-wide transcriptomic analysis of MIAT null mouse hearts identifies Hoxa4 as a novel downstream target of the MIAT/miR-150 axis. Hoxa4 is upregulated in cardiac fibroblasts isolated from ischemic myocardium and subjected to hypoxia/reoxygenation. HOXA4 is also upregulated in patients with HF. Moreover, Hoxa4 deficiency in mice protects the heart from MI. Lastly, protective actions of cardiac fibroblast miR-150 are partially attributed to the direct and functional repression of profibrotic Hoxa4. CONCLUSIONS: Our findings delineate a pivotal functional interaction among MIAT, miR-150, and Hoxa4 as a novel regulatory mechanism pertinent to ischemic HF.
BACKGROUND: MicroRNA-150 (miR-150) plays a protective role in heart failure (HF). Long noncoding RNA, myocardial infarction-associated transcript (MIAT) regulates miR-150 function in vitro by direct interaction. Concurrent with miR-150 downregulation, MIAT is upregulated in failing hearts, and gain-of-function single-nucleotide polymorphisms in MIAT are associated with increased risk of myocardial infarction (MI) in humans. Despite the correlative relationship between MIAT and miR-150 in HF, their in vivo functional relationship has never been established, and molecular mechanisms by which these 2 noncoding RNAs regulate cardiac protection remain elusive. METHODS: We use MIAT KO (knockout), Hoxa4 (homeobox a4) KO, MIAT TG (transgenic), and miR-150 TG mice. We also develop DTG (double TG) mice overexpressing MIAT and miR-150. We then use a mouse model of MI followed by cardiac functional, structural, and mechanistic studies by echocardiography, immunohistochemistry, transcriptome profiling, Western blotting, and quantitative real-time reverse transcription-polymerase chain reaction. Moreover, we perform expression analyses in hearts from patients with HF. Lastly, we investigate cardiac fibroblast activation using primary adult human cardiac fibroblasts and in vitro assays to define the conserved MIAT/miR-150/HOXA4 axis. RESULTS: Using novel mouse models, we demonstrate that genetic overexpression of MIAT worsens cardiac remodeling, while genetic deletion of MIAT protects hearts against MI. Importantly, miR-150 overexpression attenuates the detrimental post-MI effects caused by MIAT. Genome-wide transcriptomic analysis of MIAT null mouse hearts identifies Hoxa4 as a novel downstream target of the MIAT/miR-150 axis. Hoxa4 is upregulated in cardiac fibroblasts isolated from ischemic myocardium and subjected to hypoxia/reoxygenation. HOXA4 is also upregulated in patients with HF. Moreover, Hoxa4 deficiency in mice protects the heart from MI. Lastly, protective actions of cardiac fibroblast miR-150 are partially attributed to the direct and functional repression of profibrotic Hoxa4. CONCLUSIONS: Our findings delineate a pivotal functional interaction among MIAT, miR-150, and Hoxa4 as a novel regulatory mechanism pertinent to ischemic HF.
Authors: Azra Krek; Dominic Grün; Matthew N Poy; Rachel Wolf; Lauren Rosenberg; Eric J Epstein; Philip MacMenamin; Isabelle da Piedade; Kristin C Gunsalus; Markus Stoffel; Nikolaus Rajewsky Journal: Nat Genet Date: 2005-04-03 Impact factor: 38.330
Authors: H A Drabkin; C Parsy; K Ferguson; F Guilhot; L Lacotte; L Roy; C Zeng; A Baron; S P Hunger; M Varella-Garcia; R Gemmill; F Brizard; A Brizard; J Roche Journal: Leukemia Date: 2002-02 Impact factor: 11.528
Authors: Muhammad S Beg; Andrew J Brenner; Jasgit Sachdev; Mitesh Borad; Yoon-Koo Kang; Jay Stoudemire; Susan Smith; Andreas G Bader; Sinil Kim; David S Hong Journal: Invest New Drugs Date: 2016-12-05 Impact factor: 3.850
Authors: Christopher J Rhodes; John Wharton; Reinier A Boon; Tino Roexe; Hilda Tsang; Beata Wojciak-Stothard; Anob Chakrabarti; Luke S Howard; J Simon R Gibbs; Allan Lawrie; Robin Condliffe; Charles A Elliot; David G Kiely; Les Huson; Hossein A Ghofrani; Henning Tiede; Ralph Schermuly; Andreas M Zeiher; Stefanie Dimmeler; Martin R Wilkins Journal: Am J Respir Crit Care Med Date: 2012-12-06 Impact factor: 21.405